Medpace Holdings Company Profile (NASDAQ:MEDP)

Medpace Holdings trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings, Inc. (NASDAQ:MEDP) announced its quarterly earnings results on Monday, July, 31st. The company reported $0.38 EPS for the quarter, topping the Zacks' consensus estimate of $0.30 by $0.08. The business had revenue of $94.60 million for the quarter, compared to analysts' expectations of $92.71 million. Medpace Holdings had a return on equity of 9.32% and a net margin of 5.37%. The business's quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the previous year, the firm earned $0.45 EPS. View Medpace Holdings' Earnings History.

Medpace Holdings is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for Medpace Holdings.

Medpace Holdings updated its FY17 earnings guidance on Monday, July, 31st. The company provided earnings per share guidance of $1.36-1.46 for the period, compared to the Thomson Reuters consensus estimate of $1.35. The company issued revenue guidance of $373-385 million, compared to the consensus revenue estimate of $376.90 million.

6 brokers have issued twelve-month target prices for Medpace Holdings' shares. Their forecasts range from $31.00 to $36.00. On average, they anticipate Medpace Holdings' stock price to reach $34.00 in the next twelve months. View Analyst Ratings for Medpace Holdings.

Here are some recent quotes from research analysts about Medpace Holdings stock:

• 1. According to Zacks Investment Research, "Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization which provides Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace Holdings, Inc. is headquartered in Cincinnati, Ohio. " (8/3/2017)
• 2. Jefferies Group LLC analysts commented, "Medpace boasts eye-popping margin, strong cash flow, and an enticing correlation to fast growing biotech customers. With its group-high valuation, MEDP's risk, in our view, is that investors have looked through management's "conservative" guidance to upsides, akin to prior CRO post-IPO performances. 1.05x BtB, lower 2017 revenue guidance, and in-line EPS will likely pressure the stock a little on Tuesday." (2/28/2017)

Some companies that are related to Medpace Holdings include Ironwood Pharmaceuticals (IRWD), Intrexon Corporation (XON), Blueprint Medicines Corporation (BPMC), Foundation Medicine (FMI), Global Blood Therapeutics (GBT), Esperion Therapeutics (ESPR), Momenta Pharmaceuticals (MNTA), Genus plc (GNS), Genomic Health (GHDX), Albany Molecular Research (AMRI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), BeyondSpring (BYSI), Immunomedics (IMMU), Editas Medicine (EDIT), Heron Therapeutics (HRTX), Arena Pharmaceuticals (ARNA), Spectrum Pharmaceuticals (SPPI) and Cellectis S.A. (CLLS).

Medpace Holdings' management team includes the folowing people:

• August J. Troendle M.D., Chairman of the Board, President, Chief Executive Officer
• Jesse J. Geiger CPA, Chief Financial Officer, Chief Operating Officer - Laboratory Operations
• Susan E. Burwig, Executive Vice President - Operations
• Penelope J. Bucknell, Vice President - Human Resources
• Stephen P. Ewald J.D., General Counsel, Corporate Secretary
• Anastasya Molodykh, Director
• John R. Richardson, Director
• Bruce Brown, Independent Director
• Brian T. Carley, Independent Director
• Robert O. Kraft, Independent Director

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace Holdings' stock is owned by many different of retail and institutional investors. Top institutional investors include CINVEN CAPITAL MANAGEMENT (V) GENERAL PARTNER LTD (56.40%), Vanguard Group Inc. (2.57%), Bernzott Capital Advisors (1.46%), Acadian Asset Management LLC (1.19%), Granite Investment Partners LLC (0.69%) and Redmile Group LLC (0.57%). Company insiders that own Medpace Holdings stock include August J Troendle and Susan E Burwig. View Institutional Ownership Trends for Medpace Holdings.

Medpace Holdings' stock was sold by a variety of institutional investors in the last quarter, including TIAA CREF Investment Management LLC, Citadel Advisors LLC, Spark Investment Management LLC, Teachers Advisors LLC, Russell Investments Group Ltd., Wells Fargo & Company MN, California State Teachers Retirement System and OxFORD Asset Management LLP. View Insider Buying and Selling for Medpace Holdings.

Medpace Holdings' stock was bought by a variety of institutional investors in the last quarter, including Bernzott Capital Advisors, Granite Investment Partners LLC, Redmile Group LLC, Ameriprise Financial Inc., Vanguard Group Inc., Acadian Asset Management LLC, Fisher Asset Management LLC and Prudential Financial Inc.. Company insiders that have bought Medpace Holdings stock in the last two years include August J Troendle and Susan E Burwig. View Insider Buying and Selling for Medpace Holdings.

Shares of Medpace Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Medpace Holdings stock can currently be purchased for approximately $31.65.